Protagenic Therapeutics, Inc.\new Debt Securities, Available-for-sale, Realized Loss
Protagenic Therapeutics, Inc.\new (PTIX) reported Debt Securities, Available-for-sale, Realized Loss of $46.05 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2023-03-31
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, realized loss for the quarter ending 2022-12-31 was $6.07K.
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, realized loss for the quarter ending 2022-09-30 was $11.78K.
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, realized loss for the quarter ending 2022-06-30 was $23.25K.
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, realized loss for the quarter ending 2022-03-31 was $4.96K.
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, realized loss for fiscal 2022 was $46.05K, a 1752.41% increase from fiscal 2021.
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, realized loss for fiscal 2021 was $2.49K.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|---|
| 2022-12-31 | $6.07K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $17.85K derived: sum of 2 quarters · filed 2023-03-31 | $41.09K derived: sum of 3 quarters · filed 2023-03-31 | $46.05K 10-K · filed 2023-03-31 |
| 2022-09-30 | $11.78K 10-Q · filed 2022-11-14 | $35.03K derived: sum of 2 quarters · filed 2022-11-14 | $39.99K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $23.25K 10-Q · filed 2022-08-11 | $28.20K 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $4.96K 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $2.49K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |